# dry eye disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/dry-eye-disease

> 2 upcoming FDA catalysts in dry eye disease: bl1107 low dose (BLCO) on February 2027 (primary completion); bl1107 low dose (BLCO) on Feb to May 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 2, 2025 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20250402.pdf%22)) |
| April 3, 2025 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed | "On April 3, 2025, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter ("2025 Complete Response Letter") from the U.S. Food & Drug Administration ("FDA") regarding the Company's resubmitted New Drug Application ("resubmitted NDA") for reproxalap, an investigational drug candidate, for the treatment of dry eye disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm)) |
| March 16, 2026 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20260316.pdf%22)) |
| May 28, 2026 | [Xiidra (lifitegrast) primary completion](https://sec-api.dev/pdufa/lifitegrast) | BLCO | Dry Eye Disease | completed | "NCT07128628 (A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07128628)) |
| August 21, 2026 | [ABBV-444 primary completion](https://sec-api.dev/pdufa/abbv-444) | ABBV | Dry Eye Disease | completed | "NCT07284381 (A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-21 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284381)) |
| Aug to Nov 2026 | [ABBV-444 topline data readout](https://sec-api.dev/pdufa/abbv-444) | ABBV | Dry Eye Disease | scheduled | "NCT07284381 (A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-21 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284381)) |
| September 29, 2026 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "Based on the Type D meeting, on September 29, 2026, Aldeyra issued a press release (the Press Release) announcing the intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND), appealing the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application for reproxalap for the treatment of dry eye disease, and the extension of Aldeyra's projected operational cash runway into 2029." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-20260929.htm)) |
| February 2027 | [Bl1107 low dose primary completion](https://sec-api.dev/pdufa/bl1107) | BLCO | Dry Eye Disease | scheduled | "NCT07778888 (BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778888)) |
| Feb to May 2027 | [Bl1107 low dose topline data readout](https://sec-api.dev/pdufa/bl1107) | BLCO | Dry Eye Disease | scheduled | "NCT07778888 (BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778888)) |

## Drugs

- [Reproxalap](https://sec-api.dev/pdufa/reproxalap) (ALDX)
- [Xiidra (lifitegrast)](https://sec-api.dev/pdufa/lifitegrast) (BLCO)
- [ABBV-444](https://sec-api.dev/pdufa/abbv-444) (ABBV)
- [Bl1107 low dose](https://sec-api.dev/pdufa/bl1107) (BLCO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/dry-eye-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "dry eye disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/dry-eye-disease

```bibtex
@misc{secapidev_indications_dry_eye_disease_20261116,
  title        = {dry eye disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/dry-eye-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_dry_eye_disease_20261116","title":"dry eye disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/dry-eye-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
